Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145)
NCT ID: NCT00163436
Last Updated: 2016-11-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
450 participants
INTERVENTIONAL
2005-09-30
2006-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ciclesonide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of persistent bronchial asthma for at least 6 months
* Good health with the exception of asthma
Exclusion Criteria
* Smoking history with ≥10 cigarette pack years
* Pregnancy
* Intention to become pregnant
* Breast feeding
* Lack of safe contraception
* Previous enrolment into the current study
12 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca AstraZeneca
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Altana Pharma/Nycomed
La Malbaie, Quebec, , Canada
Altana Pharma/Nycomed
London, , Canada
Altana Pharma/Nycomed
London,ON, , Canada
Altana Pharma/Nycomed
Mississauga, , Canada
Altana Pharma/Nycomed
Montreal, Quebec, , Canada
Altana Pharma/Nycomed
Québec, , Canada
Altana Pharma/Nycomed
Richmond Hill, , Canada
Altana Pharma/Nycomed
Sainte-Foy, Quebec, , Canada
Altana Pharma/Nycomed
Saskatoon,SK, , Canada
Altana Pharma/Nycomed
Scarborough,ON, , Canada
Altana Pharma/Nycomed
Toronto, , Canada
Altana Pharma/Nycomed
Vancouver, BC, , Canada
Altana Pharma/Nycomed
Winnipeg, , Canada
Altana Pharma/Nycomed
Winnipeg MB, , Canada
Altana Pharma/Nycomed
Woodstock, , Canada
Altana Pharma/Nycomed
Aix-en-Provence, , France
Altana Pharma/Nycomed
Chauny, , France
Altana Pharma/Nycomed
Ferolles-Attily, , France
Altana Pharma/Nycomed
Grasse, , France
Altana Pharma/Nycomed
La Rochelle, , France
Altana Pharma/Nycomed
La Teste-de-Buch, , France
Altana Pharma/Nycomed
Libourne, , France
Altana Pharma/Nycomed
Lille, , France
Altana Pharma/Nycomed
Martigues, , France
Altana Pharma/Nycomed
Montbrison, , France
Altana Pharma/Nycomed
Montpellier, , France
Altana Pharma/Nycomed
Nice, , France
Altana Pharma/Nycomed
Nîmes, , France
Altana Pharma/Nycomed
Saint-Laurent-du-Var, , France
Altana Pharma/Nycomed
Saint-Quentin, , France
Altana Pharma/Nycomed
Berlin, , Germany
Altana Pharma/Nycomed
Berlin, , Germany
Altana Pharma/Nycomed
Oschersleben, , Germany
Altana Pharma/Nycomed
Rüdersdorf, , Germany
Altana Pharma/Nycomed
Schwetzingen, , Germany
Altana Pharma/Nycomed
Weinheim, , Germany
Altana Pharma/Nycomed
Balassagyarmat, , Hungary
Altana Pharma/Nycomed
Budapest, , Hungary
Altana Pharma/Nycomed
Budapest, , Hungary
Altana Pharma/Nycomed
Budapet, , Hungary
Altana Pharma/Nycomed
Érd, , Hungary
Altana Pharma/Nycomed
Gyula, , Hungary
Altana Pharma/Nycomed
Komárom, , Hungary
Altana Pharma/Nycomed
Miskolc, , Hungary
Altana Pharma/Nycomed
Mosdós, , Hungary
Altana Pharma/Nycomed
Nyiregyháza, , Hungary
Altana Pharma/Nycomed
Pécs, , Hungary
Altana Pharma/Nycomed
Szeged, , Hungary
Altana Pharma/Nycomed
Székesfehérvár, , Hungary
Altana Pharma/Nycomed
Bangalore, , India
Altana Pharma/Nycomed
Chennai, , India
Altana Pharma/Nycomed
Coimbatore, , India
Altana Pharma/Nycomed
Coimbatore, , India
Altana Pharma/Nycomed
Coimbatore, Tamilnadu, , India
Altana Pharma/Nycomed
Goa, , India
Altana Pharma/Nycomed
Kalaburagi, , India
Altana Pharma/Nycomed
Mumbai, , India
Altana Pharma/Nycomed
Mumbai, Dadar (E), , India
Altana Pharma/Nycomed
Pune, , India
Altana Pharma/Nycomed
Florence, , Italy
Altana Pharma/Nycomed
Milan, , Italy
Altana Pharma/Nycomed
Milan, , Italy
Altana Pharma/Nycomed
Milan, , Italy
Altana Pharma/Nycomed
Napoli, , Italy
Altana Pharma/Nycomed
Pordenone, , Italy
Altana Pharma/Nycomed
Verona, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BY9010-MI-145-RDS-2007-05-21.pdf
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BY9010/M1-145
Identifier Type: -
Identifier Source: org_study_id